|
1
|
Gurcan O, Gurcay AG, Kazanci A, Yildirim
AE, Turkoglu OF, Komurcu HF and Beskonakli E: Trigeminal neuralgia
as an unusual isolated symptom of pituitary Adenoma: Case report
and review of the literature. Turk Neurosurg. 26:180–183.
2016.PubMed/NCBI
|
|
2
|
Bengtsson D, Schrøder HD, Andersen M,
Maiter D, Berinder K, Rasmussen U Feldt, Rasmussen ÅK, Johannsson
G, Hoybye C, Van Der Lely AJ, et al: Long-term outcome and MGMT as
a predictive marker in 24 patients with atypical pituitary adenomas
and pituitary carcinomas given treatment with temozolomide. J Clin
Endocrinol Metab. 100:1689–1698. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McCormack A, Kaplan W, Gill AJ, Little N,
Cook R, Robinson B and Clifton-Bligh R: MGMT expression and
pituitary tumours: Relationship to tumour biology. Pituitary.
16:208–219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen YP, Hou XY, Yang CS, Jiang XX, Yang
M, Xu XF, Feng SX, Liu YQ and Jiang G: DNA methylation and histone
acetylation regulate the expression of MGMT and chemosensitivity to
temozolomide in malignant melanoma cell lines. Tumour Biol.
37:11209–11218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wickström M, Dyberg C, Milosevic J, Einvik
C, Calero R, Sveinbjörnsson B, Sandén E, Darabi A, Siesjö P, Kool
M, et al: Wnt/β-catenin pathway regulates MGMT gene expression in
cancer and inhibition of Wnt signalling prevents. chemoresistance.
6:89042015.
|
|
6
|
Khattak MN, Buchfelder M, Kleindienst A,
Schöfl C and Kremenevskaja N: CRH and SRIF have opposite effects on
the Wnt/β-catenin signalling pathway through PKA/GSK-3β in
corticotroph pituitary cells. Cancer Invest. 28:797–805. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Das A, Miller R, Lee P, Holden CA,
Lindhorst SM, Jaboin J, Vandergrift WA III, Banik NL, Giglio P,
Varma AK, et al: A novel component from citrus, ginger, and
mushroom family exhibits antitumor activity on human meningioma
cells through suppressing the Wnt/β-catenin signaling pathway.
Tumour Biol. 36:7027–7034. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xing Y, Tu J, Zheng L, Guo L and Xi T:
Anti-angiogenic effect of tanshinone IIA involves inhibition of the
VEGF/VEGFR2 pathway in vascular endothelial cells. Oncol Rep.
33:163–170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bai Y, Zhang L, Fang X and Yang Y:
Tanshinone IIA enhances chemosensitivity of colon cancer cells by
suppressing nuclear factor-κB. Exp Ther Med. 11:1085–1089. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Prokhorova EA, Zamaraev AV, Kopeina GS,
Zhivotovsky B and Lavrik IN: Role of the nucleus in apoptosis:
Signaling and execution. Cell Mol Life Sci. 72:4593–4612. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jellinger KA: Challenges in neuronal
apoptosis. Curr Alzheimer Res. 3:377–391. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hunter AL, Choy JC and Granville DJ:
Detection of apoptosis in cardiovascular diseases. Methods Mol Med.
112:277–289. 2005.PubMed/NCBI
|
|
13
|
Ding L, Ding L, Wang S, Wang S, Wang W,
Wang W, Lv P, Lv P, Zhao D, Zhao D, et al: Tanshinone IIA affects
autophagy and apoptosis of glioma cells by inhibiting
phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin
signaling pathway. Pharmacology. 99:188–195. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang ST, Huang CC, Huang WL, Lin TK, Liao
PL, Wang PW, Liou CW and Chuang JH: Tanshinone IIA induces
intrinsic apoptosis in osteosarcoma cells both in vivo and in vitro
associated with mitochondrial dysfunction. Sci Rep. 7:403822017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu J, Wang X, Li Y and Tang B: Tanshinone
IIA suppresses gastric cancer cell proliferation and migration by
downregulation of FOXM1. Oncol Rep. 37:1394–1400. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wickström M, Dyberg C, Milosevic J, Einvik
C, Calero R, Sveinbjörnsson B, Sandén E, Darabi A, Siesjö P, Kool
M, et al: Wnt/β-catenin pathway regulates MGMT gene expression in
cancer and inhibition of Wnt signalling prevents chemoresistance.
Nat Commun. 6:89042015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Formosa R, Gruppetta M, Falzon S, Santillo
G, DeGaetano J, Xuereb-Anastasi A and Vassallo J: Expression and
clinical significance of Wnt players and survivin in pituitary
tumours. Endocr Pathol. 23:123–131. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maïza JC and Caron P: Pituitary carcinomas
and aggressive adenomas: An overview and new therapeutic options.
Ann Endocrinol (Paris). 70 Suppl 1:S12–S19. 2009.(In French).
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang BY, Cao LY and Fu XG: Effects of
tanshinone IIA on Wnt/beta-catenin signaling pathway of high
glucose induced renal tubular epithelial cell transdifferentiation.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 32:965–969. 2012.(In Chinese).
PubMed/NCBI
|
